Literature DB >> 31740461

Benefits and harms of aspirin to reduce colorectal cancer risk: a cross-sectional study of methods to communicate risk in primary care.

Peter Nguyen1, Jennifer McIntosh1, Adrian Bickerstaffe2, Sanjaya Maddumarachchi2, Kara-Lynne Cummings3, Jon D Emery4.   

Abstract

BACKGROUND: New Australian guidelines recommend that GPs actively consider prescribing low-dose aspirin to patients aged 50-70 years to reduce their risk of developing colorectal cancer (CRC). Patients and GPs need to understand the relative benefits and harms to support informed decision making. AIM: To develop and examine different methods to communicate the benefits and harms of taking aspirin for CRC prevention. DESIGN AND
SETTING: A cross-sectional, vignette study with patients aged 50-70 years consecutively recruited from general practices in Melbourne, Australia, between July and August 2018.
METHOD: Summary estimates from meta-analyses of the effects of aspirin on the incidence of CRC, cardiovascular disease, gastrointestinal bleeding, and incidence rates in the Australian population to estimate outcomes in a hypothetical population of 10 000 people aged 50-70 years. These estimates were presented using four different risk communication formats. Participants were shown these different formats and asked if they would take aspirin to prevent CRC.
RESULTS: A total of 313 participants were recruited (95.1% recruitment rate), of whom 304 completed the study. Most participants (71.7-75.3%) reported they would take aspirin irrespective of risk format presented. Bar charts (odds ratio [OR] 1.20, 95% confidence intervals [CI] = 1.01 to 1.44) and expected frequency trees (OR 1.18, 95% CI = 0.99 to 1.41) were more strongly associated with the intentions to take aspirin compared with icon arrays. Bar charts were most preferred for presenting risk information.
CONCLUSION: A large proportion of participants in this study intended to take aspirin to reduce their CRC risk regardless of risk communication format. Bar charts and expected frequency trees were the preferred methods to present the benefits and harms of taking aspirin to prevent CRC. © British Journal of General Practice 2019.

Entities:  

Keywords:  aspirin; colorectal cancer; decision making; general practice; primary health care; risk communication

Mesh:

Substances:

Year:  2019        PMID: 31740461      PMCID: PMC6863681          DOI: 10.3399/bjgp19X706613

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  17 in total

1.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

Authors:  Peter M Rothwell; Michelle Wilson; Carl-Eric Elwin; Bo Norrving; Ale Algra; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-10-21       Impact factor: 79.321

2.  The CRISP-Q study: Communicating the risks and benefits of colorectal cancer screening

Authors:  Grace Y Kim; Jennifer G Walker; Adrian Bickerstaffe; Nadira Hewabandu; Marie Pirotta; Louisa Flander; Mark Jenkins; Jon D Emery
Journal:  Aust J Gen Pract       Date:  2018-03

3.  Designing Visual Aids That Promote Risk Literacy: A Systematic Review of Health Research and Evidence-Based Design Heuristics.

Authors:  Rocio Garcia-Retamero; Edward T Cokely
Journal:  Hum Factors       Date:  2017-02-13       Impact factor: 2.888

4.  Understanding the Harms and Benefits of Cancer Screening: A Model of Factors That Shape Informed Decision Making.

Authors:  Dafina Petrova; Rocio Garcia-Retamero; Edward T Cokely
Journal:  Med Decis Making       Date:  2015-06-04       Impact factor: 2.583

5.  Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.

Authors:  Jennifer G McIntosh; Jesse Minshall; Sibel Saya; Adrian Bickerstaffe; Nadira Hewabandu; Ashleigh Qama; Jon D Emery
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

6.  Utilization of Continuous "Spinners" to Communicate Risk.

Authors:  Rachel F Eyler; Sara Cordes; Benjamin R Szymanski; Liana Fraenkel
Journal:  Med Decis Making       Date:  2017-05-10       Impact factor: 2.583

7.  Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs.

Authors:  Brian J Zikmund-Fisher; Peter A Ubel; Dylan M Smith; Holly A Derry; Jennifer B McClure; Azadeh Stark; Rosemarie K Pitsch; Angela Fagerlin
Journal:  Patient Educ Couns       Date:  2008-11

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

Authors:  Peter M Rothwell; F Gerald R Fowkes; Jill F F Belch; Hisao Ogawa; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-12-06       Impact factor: 79.321

Review 10.  Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers.

Authors:  Lyndal J Trevena; Brian J Zikmund-Fisher; Adrian Edwards; Wolfgang Gaissmaier; Mirta Galesic; Paul K J Han; John King; Margaret L Lawson; Suzanne K Linder; Isaac Lipkus; Elissa Ozanne; Ellen Peters; Danielle Timmermans; Steven Woloshin
Journal:  BMC Med Inform Decis Mak       Date:  2013-11-29       Impact factor: 2.796

View more
  3 in total

1.  Clinicians' opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50-70 years: a qualitative study.

Authors:  Shakira Milton; Jennifer McIntosh; Thivagar Yogaparan; Pavithran Alphonse; Sibel Saya; Napin Karnchanachari; Peter Nguyen; Phyllis Lau; Finlay Macrae; Jon Emery
Journal:  BMJ Open       Date:  2021-02-05       Impact factor: 2.692

Review 2.  Aspirin use for cancer prevention: A systematic review of public, patient and healthcare provider attitudes and adherence behaviours.

Authors:  Kelly E Lloyd; Louise H Hall; Natalie King; Rachael J Thorneloe; Rocio Rodriguez-Lopez; Lucy Ziegler; David G Taylor; Mairead MacKenzie; Samuel G Smith
Journal:  Prev Med       Date:  2021-11-09       Impact factor: 4.018

3.  An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases: a study protocol for the SITA (Should I Take Aspirin?) trial.

Authors:  Shakira Milton; Jennifer McIntosh; Finlay Macrae; Patty Chondros; Lyndal Trevena; Mark Jenkins; Fiona M Walter; Natalie Taylor; Lucy Boyd; Sibel Saya; Napin Karnchanachari; Kitty Novy; Carmody Forbes; Javiera Martinez Gutierrez; Kate Broun; Sara Whitburn; Sarah McGill; George Fishman; Julie Marker; Max Shub; Jon Emery
Journal:  Trials       Date:  2021-07-15       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.